With the cost of healthcare and drug discovery continuing to rise and value-based contracting gaining traction, demonstrating a product’s economic value compared to existing competitor products is more important than ever. Drugs today need to be reimbursable, not just approvable, writes MMIT’s Dinesh Kabaleeswaran in an article for PharmExec.
We're looking for agile, growth-oriented team players who are passionate about client success and helping patients get access to the therapies they need.Work with us
Have questions about Norstella or its brands? Or do you want to know more about how to solve your market access challenges?We want to hear from you